Anti-SARS-CoV-2 Antibody Testing: Role and Indications
Journal of Clinical Medicine · 08.12.2023 · 12 (24) · 7575
DOI: 10.3390/jcm12247575 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 08.12.2023. Verfasst von Sylvia Mink und 1 weiteren Autor:innen. Beteiligte Einrichtung: Central Medical Laboratories, 6800 Feldkirch, Austria. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Since the onset of the COVID-19 pandemic in March 2020, over 769 million confirmed COVID-19 cases, including close to 7 million COVID-19-related deaths, have been reported. Although mortality rates have dropped notably compared to the first months of the pandemic, spikes in reported cases and mortality rates continue to be registered. Both recent spikes in case numbers and the continued emergence of new variants suggest that vulnerable patient groups, including older adults, immunocompromised patients, and patients with severe comorbidities, are going to continue to be affected by COVID-19. In order to curb the pandemic, relieve the pressure on primary care facilities, and reduce mortality rates, global vaccination programs have been established by the WHO, with over 13.5 billion vaccine doses having been administered globally. In most immunocompetent individuals, vaccination against COVID-19 results in the production of anti-SARS-CoV-2 spike antibodies. However, certain patient subsets have inadequate or reduced immune responses, and immune responses are known to decrease with age. General recommendations on the timing of booster vaccinations may therefore be insufficient to protect vulnerable patients. This review aims to evaluate the clinical role of anti-SARS-CoV-2 antibodies, focusing on measurement indications, prognostic value, and potential as a correlate of protection to guide future booster vaccination strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Central Medical Laboratories, 6800 Feldkirch, Austria.
- Private University in the Principality of Liechtenstein, 9495 Triesen, Liechtenstein.
Zitieren
APA
Mink, S., & Fraunberger, P. (2023). Anti-SARS-CoV-2 Antibody Testing: Role and Indications. Journal of Clinical Medicine, 12(24), 7575. https://doi.org/10.3390/jcm12247575
Vancouver
Mink S, Fraunberger P. Anti-SARS-CoV-2 Antibody Testing: Role and Indications. Journal of Clinical Medicine. 2023;12(24):7575. doi:10.3390/jcm12247575
BibTeX
@article{Mink2023,
author = {Mink, Sylvia and Fraunberger, Peter},
title = {Anti-SARS-CoV-2 Antibody Testing: Role and Indications},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {24},
pages = {7575},
doi = {10.3390/jcm12247575}
}
EUVIMED